Skip to main content
. Author manuscript; available in PMC: 2010 Oct 20.
Published in final edited form as: J Neuropsychiatry Clin Neurosci. 2009 Summer;21(3):299–306. doi: 10.1176/appi.neuropsych.21.3.299

Table 1.

Demographic and disease severity data for participants*

PPA bvFTD PrAD

N 16 10 23
Age 68.44 (8.16) 63.70 (6.61) 79.46 (8.00)
Education (Years) 15.57 (2.79) 15.90 (2.33) 13.50 (3.53)
Duration of disease (Years) 4.32 (1.74) 4.90 (2.64) 5.58 (3.59)
CDR 0.53 (0.38) 1.11 (0.55) 1.27 (0.49)
MMSE (max = 30) 20.88 (7.56) 24.00 (4.16) 20.21 (4.58)
NPI-Q (symptoms, max = 12) 2.19 (2.23) 4.22 (2.39) 3.39 (2.70)
BNT (max = 60) 38.92 (20.84) 41.70 (18.67) 38.52 (13.49)
*

Mean scores (with standard deviations) for CDR, MMSE, NPI-Q (Neuropsychiatric Inventory Questionnaire) and BNT (Boston Naming Test). ANOVA with planned comparisons indicated that PrAD patients were significantly older than PPA and bvFTD patients (p<.005). PPA patients had significantly lower CDR scores and ADL-Q scores than bvFTD or PrAD patients (p<.005).